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A B S T R A C T   
The aim of this study is to formulate and optimize novel transfersome formulations for pulmonary drug delivery. 
Transfersome formulations (F1 – F18) were prepared by a thin-film method using three phospholipids (Soya 
phosphatidylcholine (SPC), Dimyristoly phosphatidylcholine (DMPC) and Hydrogenated soya phosphatidyl-
choline (HSPC)), in combination with three different surfactants (Tween 80, Span 80 and Span 20) with or 
without cholesterol, employing Beclomethasone dipropionate (BDP) as the model drug. Nano-transfersome 
formulations post-extrusion were delivered to a Two-stage Impinger (TSI) via three medical nebulizers (i.e. 
Air-jet, Ultrasonic and Vibrating mesh nebulizer). Based on the physicochemical properties, formulations F1 (SPC 
and Tween 80), F7 (DMPC and Tween 80) and F13 (HSPC and Tween 80) demonstrated significantly smaller 
VMD (162.34 ± 6.48, 198.66 ± 6.64, and 183.52 ± 7.34 nm), and significantly higher entrapment efficiency 
(97.56 ± 2.45, 95.67 ± 4.26 and 95.06 ± 3.38%). Based on nebulization performance, the Ultrasonic nebulizer 
exhibited the shortest nebulization time for formulations F1, F7 and F13 (i.e. 17.88 ± 2.45, 19.26 ± 2.04 and 
19.59 ± 2.12 min), and higher output rate (212.04 ± 11.54, 194.61 ± 10.27 and 192.43 ± 9.84 mg/min), when 
compared to Air-jet and Vibrating mesh nebulizers. Irrespective of nebulizer type, significantly higher BDP 
deposition was observed in the lower stage of TSI for the F1 formulation (on average of 61%), whereas a higher 
amount of BDP was deposited in the upper stage of TSI using the F7 formulations (49%). Moreover, Formulation 
F1 in combination with Air-jet nebulizer demonstrated higher emitted dose (ED) and fine particle fraction (FPF) 
(82% and 83%), when compared to the counterpart formulations and nebulizer types investigated. This study has 
demonstrated that based on nebulizer performance, BDP deposition and formulation type; the F1 formulation in 
combination with an Air-jet nebulizer is most optimal for lower respiratory tract deposition, whereas the F7 
formulation in combination with an Ultrasonic nebulizer is ideal for upper respiratory tract deposition.   
1. Introduction 
Liposomes/proliposomes, ethosomes, transfersomes/pro-
transfersomes, solid lipid nanoparticles, nanostructured lipid carriers 
and emulsions offer many advantages than their other counterpart de-
livery systems [1–4]. One of the key advantages of lipid-based formu-
lations is that they encapsulate lipophilic as well as hydrophilic active 
pharmaceutical agents within the concentric bilayers and central core, 
simultaneously. Phospholipids self-assemble themselves into vesicles 
upon direct contact with aqueous medium, when exposed above their 
phase transition temperature. They are considered both biocompatible 
and biodegradable due to the nature of phospholipid. 
Transfersomes are also referred to as elastic or deformable liposomes 
due to the presence of surfactants, embedded in the bilayers, making 
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them more flexible and less rigid, in order to pass through the pores as 
well as offering smaller vesicle size than the traditional liposomes [5]. 
Essentially, deformability of the concentric bilayers increases when the 
bilayers of vesicles are destabilized, which are directly related to the 
surfactant or edge activator containing a single chain with a high radius 
of curvature. Examples of these surfactants employed in transfersomes 
include; Tween 80, Tween 20, Span 80, Span 20, dipotassium glycyr-
rhizinate, sodium deoxycholate and sodium cholate [6,7]. Transfersome 
vesicles have captured increased interest in both the cosmetics and 
pharmaceutical industry due to their small vesicle size and improved 
flexibility. In the cosmetics industry, transfersomes are an ideal vesic-
ular system for encapsulating and delivering active agents, as well as 
plant extracts as an aqueous suspension or following its incorporation 
into creams, suspensions, ointments, serums, toners and lotions for skin 
delivery in order to achieve anti-oxidant, anti-aging, anti-perspirant, 
skin lightning, moisturizing and photo protective effects. In the phar-
maceutical industry, transfersomes have been employed for the delivery 
of various active ingredients via buccal [8], pulmonary [9], transdermal 
[10], parenteral [11] and topical delivery [12]. 
The pulmonary system is a non-invasive route of drug administra-
tion, offering a large surface area (approximately 100 m2) [13]. This 
route has been historically used for the inhalation of Atropa belladonna 
leaves for treating coughs, circa 4000 years ago [14]. Beclomethasone 
dipropionate (BDP) is a commercially available steroidal drug, used as 
prophylaxis in asthma via inhalation. A number of different brands such 
as Asmabec are available as a dry powder inhalers, whereas QVAR and 
Clenil are accessible in pressurised meter dose inhalers, containing BDP. 
BDP has been studied in a number of lipid-based aqueous formulations, 
as well as in a dry powder form (prepared via spray drying or freeze 
drying) targeting the pulmonary system including; liposomes [15–18], 
micelles [19], microspheres [20], niosomes [21], solid lipid nano-
particles [22] and nanostructured lipid carriers [23,24] in order to 
solubilize the drug and achieve localized effect for longer period of time. 
Nebulizers have been employed for a plethora of formulations for 
pulmonary administration. The three basic types of medical nebulizers 
are classified based on their mechanism of generating aerosols, these 
are; Air-jet, Ultrasonic and Vibrating mesh nebulizers. Each class con-
sists of many sub types, working on the same principle, with slight 
modifications in the design. A high velocity of compressed gas is used in 
Air-jet nebulizers that convert aqueous suspensions or solutions into 
aerosols via the Bernoulli effect, where after passing the gas through a 
fine hole (termed a venture nozzle) develops a negative pressure over 
the formulation, and hence inhalable droplets are generated [25,26]. 
Additionally, droplet formation is caused by the surface tension of the 
formulation as well as baffle of the Air-jet nebulizer, where droplets 
upon generation pass through a mouthpiece for inhalation [13,27]. Ul-
trasonic nebulizers are comprised of a piezoelectric crystal, which vi-
brates at a high frequency when connected to a power supply, creating 
an energy within the stagnant aqueous formulation. This allows the 
formulation to form a fountain-like structure and hence inhalable 
droplets are generated at the apex and at the lower part of the fountain 
[13,25]. As the name indicates, the Vibrating mesh nebulizer consists of 
a perforated plate, which is also called mesh plate. Vibrations are 
created by a piezoelectric crystal, which is connected to a horn trans-
ducer. Through this transducer these vibrations are transmitted in order 
to extrude the formulation from the perforated/mesh plate to generate 
inhalable droplets [13,28]. These three nebulizers and their sub types 
have been studied extensively using various micro and nano formula-
tions in order to find the best nebulizer as well as formulation to achieve 
high drug deposition in the pulmonary system without affecting vesicle 
integrity [2]. 
In this study, various types of transfersome formulations were pre-
pared and nebulizers were employed for pulmonary drug delivery. The 
aim of this study was to develop and optimize BDP-loaded transfersome 
formulations and to investigate the impact of various factors, such as 
phospholipid type, surfactant type, inclusion or exclusion of cholesterol 
on the physicochemical properties of transfersome vesicles, including; 
VMD, polydispersity index (PDI), Zeta potential and entrapment effi-
ciency. Furthermore, different nebulizers were employed for the 
selected formulations to determine their performance in terms of 
nebulization time, sputtering time, mass output and output rate. Finally, 
deposition of BDP in Two-stage Impinger (TSI) was explored to identify 
the best combination of formulation and nebulizer type. 
2. Materials and methods 
2.1. Materials 
Soya phosphatidylcholine (SPC; Lipoid S-100; 94% purity), Dimyr-
istoly phosphatidylcholine (DMPC; 98% purity) and Hydrogenated soya 
phosphatidylcholine (HSPC; 98% purity) were purchased from Lipoid, 
Steinhausen, Switzerland. Beclomethasone dipropionate (BDP, ≥99%), 
cholesterol (≥99%), Tween 80, Span 80, Span 20 and polycarbonate 
filters with a pore sizes of 200 and 600 nm, and 25 mm in diameters 
were bought from Sigma Aldrich, UK. HPLC-grade methanol and abso-
lute ethanol were acquired from Fisher scientific, UK. 
Table 1 
Transfersome formulations (F1 – F18) were prepared using a lipid phase consisting of three phospholipids (SPC, DMPC and HSPC), three different surfactants (Tween 
80, Span 80 and Span 20) and with or without cholesterol inclusion. BDP was used as anti-asthmatic drug in all formulations, n = 3.  
Lipid phase 
Formulations Phospholipid Surfactant Cholesterol 
F1 SPC – – Tween 80 – – – 
F2 SPC – – Tween 80 – – Cholesterol 
F3 SPC – – – Span 80 – – 
F4 SPC – – – Span 80 – Cholesterol 
F5 SPC – – – – Span 20 – 
F6 SPC – – – – Span 20 Cholesterol 
F7 – DMPC – Tween 80 – – – 
F8 – DMPC – Tween 80  – Cholesterol 
F9 – DMPC – – Span 80 – – 
F10 – DMPC – – Span 80 – Cholesterol 
F11 – DMPC – – – Span 20 – 
F12 – DMPC – – – Span 20 Cholesterol 
F13 – – HSPC Tween 80 – – – 
F14 – – HSPC Tween 80 – – Cholesterol 
F15 – – HSPC – Span 80 – – 
F16 – – HSPC – Span 80 – Cholesterol 
F17 – – HSPC – – Span 20 – 
F18 – – HSPC – – Span 20 Cholesterol  
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2.2. Preparation of transfersomes via thin film method 
Transfersomes were prepared via a thin-film method, where three 
different phospholipids (SPC, DMPC or HSPC) and three different sur-
factants (i.e. Tween 80, Span 80 or Span 20) were used to prepare 18 
different transfersome formulations, employing BDP as a model drug in 
2 mol% concentration to the lipid phase (Table 1). The lipid phase (250 
mg) was comprised of phospholipid, cholesterol (with or without) and 
surfactant; where phospholipid to surfactant ratio was employed as 
75:25 w/w, and this ratio to cholesterol was used in a 1:1 M ratio 
(Table 1). Phospholipid, cholesterol (with or without), surfactant and 
BDP were dissolved in 20 ml of absolute ethanol and transferred to a 
round bottom flask (RBF) (100 ml). The RBF was attached to a rotary 
evaporator (Buchi Rotavapor R-114, Buchi, Switzerland) and lowered 
into a water bath (Buchi Water bathe B-480, Buchi, Switzerland) already 
adjusted to 45 ◦C. A negative pressure was created to evaporate organic 
solvent via a vacuum pump (Buchi Vac V-501). This process was 
continued for 1 h with a rotation speed of 270 RPM. Negative pressure 
was released and the RBF containing a thin film was detached from the 
rotary evaporator. The thin lipid film in the RBF was hydrated with 10 
ml of deionised water and agitated manually for 5 min, followed by 1 h 
annealing to form stable transfersome vesicles. The phase transition 
temperature of SPC, DMPC and HSPC is circa − 20 ◦C, 23 ◦C and 52 ◦C; 
therefore hydration and annealing both were conducting above the 
phase transition temperatures of the phospholipids incorporated. The 
hydration and annealing temperature for both SPC and DMPC formu-
lations was maintained at 30 ◦C, whereas for HSPC formulations, this 
was maintained at 60 ◦C. 
2.3. Size reduction using extrusion method 
Transfersome size was reduced using a Lipsofast extruder (Huber 
Avastin – Lipsofast LF-50, Germany). The extruder was set at tempera-
ture of 60 ◦C and nitrogen (using high pressure approximately 70 psi) 
was used to force the transfersome suspension (10 ml) through 600 nm 
filters for 5 cycles followed by passing through 200 nm filters for 5 cy-
cles, to achieve nanoparticles with uniform size distribution. 
2.4. Transfersome size and Zeta potential analysis 
Size of transfersomes also referred to as volume median diameter 
(VMD) and polydispersity index (PDI) were measured employing Dy-
namic Light Scattering (DLS), using a Zetasizer Nanoseries instrument 
(Malvern Instruments Ltd., UK). The surface charge of transfersomes was 
also identified using the Zetasizer Nanoseries via Laser Doppler Veloc-
imetry (LDV), where transfersome vesicle electrophoretic mobility in 
the suspension was determined. 
2.5. Separation and entrapment efficiency of BDP 
The transfersome suspension (0.5 ml) was placed in a Millipore 
centrifuge tube (10 KD) (Fischer Scientific, UK) and bench centrifuga-
tion (Spectrafuge 24D, Labnet International, USA) was employed using a 
speed of 13,000 RPM (15,500×g) for 30 min. This process allowed the 
separation of unentrapped drug (free drug passing through Millipore 
filter called filtrate) from the entrapped drug in transfersomes (trans-
fersomes as carrier particles are too large to pass through the Millipore 
filter). The unentrapped BDP was then analysed via HPLC (Agilent 1200 
HPLC instrument, UK). For total drug BDP analysis, 1 ml from the 
transfersome suspension was separately dissolved in 15 ml of methanol 
and quantified using HPLC in accordance to equation (1).   
BDP was assayed via HPLC using a mobile phase of methanol and 
water (75:25 v/v) with a flow rate of 1.7 ml/min and an injection vol-
ume of 20 μl. The detection wavelength was set at 239 nm with a tem-
perature adjusted to 40 ◦C. The HPLC column used was a C-18, 150 mm 
× 4.6 mm, and 5-μm column (Agilent technology, USA). 
2.6. Optimal formulation and nebulization performance 
Transfersome formulations were selected on the basis of size, Zeta 
potential and entrapment efficiency. Each formulation was then tested 
in three nebulizers: Air-jet (PARI Turboboy 5 air jet, UK), Ultrasonic 
(Uniclife rechargeable ultrasonic inhaler MY-520B, UK) and Vibrating 
mesh (Omron Micro-air U22 pocket nebulizer, UK) with a Two-stage 
Impinger (TSI) i.e. an artificial lung model as suggested by the British 
Pharmacopoeia. The TSI is comprised of an upper stage and lower stage 
(representing the upper and the lower airways), containing 7 and 30 ml 
of deionised water, respectively. The cut-off diameter between the upper 
and lower stage at 60 L/min is 6.4 μm [2,29]. Transfersome suspensions 
(5 ml) were transferred to the nebulizer reservoir of each nebulizer and 
nebulization performance was determined in terms of nebulization time, 
sputtering time, aerosol mass output and aerosol output rate. Aerosol 
mass output and aerosol output rate were calculated with the help of the 
following equations (2) and (3):   
Aerosol ​ output ​ rate ​ (mg /min)= (Weight ​ of ​ nebulized ​ formulation ​
Complete ​ nebulization ​ time ​
)
(Eq. 3) 
Furthermore, deposition of BDP in the two stages of TSI, as well as 
the formulation remained as dead or residual volume in the nebulizer 
reservoir was determined via HPLC, post nebulization. Additionally, the 
amount of BDP deposited in the upper and lower stages was determined 
as emitted dose (ED). The amount of BDP deposited in the lower stage is 
also considered as fine particle dose (FPD). The final particle fraction 
Mass ​ output ​ (%)= (
Weight ​ of ​ nebulized ​ formulation ​
Weight ​ of ​ formulation ​ present ​ in ​ the ​ nebulizer ​ prior ​ to ​ nebulization ​
)X100 (Eq. 2)   
Entrapment ​ Efficiency ​ (%)= (
​ Total ​ drug ​ loading − Unentrapped ​ drug
Total ​ drug ​ loading
) × 100 (Eq. 1)   
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Fig. 1. An average of the following six transfersome formulations (i.e. F1, F2, F7, F8, F13 and F14) were determined (each formulation in triplicate) after passing the 
vesicles through polycarbonate membrane employing five cycles using a pore size of 600 nm for, (a) volume median diameter (VMD) and, (b) polydispersity index 
(PDI); followed by passing through polycarbonate membrane employing five cycles using a pore size of 200 nm for, (c) volume median diameter (VMD) and, (d) 
polydispersity index (PDI). Data are presented as mean ± SD, n = 3. 
Fig. 2. VMD (vertical bars) and PDI (hori-
zontal lines) of transfersome formulations 
(F1 – F18), prepared from three different 
phospholipids (SPC, DMPC and HSPC), three 
surfactants (Tween 80, Span 80 and Span 
20) with and without cholesterol addition. 
Transfersome formulations prepared from 
surfactants are highlighted with different 
colours i.e. Tween 80 (F1, F2, F7, F8, F13, 
F14), Span 80 (F3, F4, F9, F10, F15, F16) 
and Span 20 (F5, F6, F11, F12, F17, F18). 
Data are mean ± SD, n = 3. (For interpre-
tation of the references to colour in this 
figure legend, the reader is referred to the 
Web version of this article.)   
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(FPF) was calculated as the percentage of ED deposited in stage 2 (i.e. 
FPD). 
2.7. Morphology studies via transmission electron microscopy (TEM) 
For TEM analysis, a drop of transfersome suspension and a drop of 
negative stain (i.e. 1% w/v phosphotungstic acid) were placed on a 
carbon coated carbon grid (400 mesh; TAAB Laboratories Equipment 
Ltd., UK). After drying (1 h), transfersome structures were observed, and 
a number of images were captured using a Philips CM 120 Bio-Twin TEM 
(Philips Electron Optics BV, Netherlands). 
2.8. Statistical analysis 
One way analysis of variance (ANOVA) and Student’s t-test was 
performed to compare more than two set and two groups of results. All 
experiments were performed in triplicate. Values of p < 0.05 were 
considered as a statistically significant difference between compared 
groups. 
3. Results and discussion 
3.1. Size reduction and size analysis 
There are many benefits associated with smaller vesicle size e.g. 
offering better uptake by cells [30] and drug deposition. With the same 
quantity of transfersome-forming materials, reduction of particle size 
may lead to higher drug entrapment. This may be directly related to the 
overall surface area, as there are a higher number of transfersomes. As 
the particle size decreases, the surface area increases and hence drug 
encapsulation. Therefore, engineering in achieving the required vesicle 
size of transfersomes is highly significant. Post size reduction, properties 
of the transfersomes were investigated in terms of size (also known as 
volume median diameter (VMD)) and size distribution (also denoted as 
polydispersity index (PDI)). Extrusion was employed for the formulated 
transfersome formulations (i.e. F1, F2, F7, F8, F13 and F14) in order to 
reduce transfersome particle size and achieve lower PDI. An average of 
these formulations with regards to VMD and PDI are shown in Fig. 1. 
Unlike probe sonication, extrusion of vesicles through polycarbonate 
membrane filter does not contaminate the formulation with any residue, 
such as titanium and hence no further purification step is required [2, 
24]. Similarly, the time required to reduce vesicle size to approximately 
200 nm by bath sonication would be significantly longer than that of 
probe sonication or the extrusion method. For these reasons extrusion 
was selected for the reduction of vesicle size in this study. In order to 
achieve particle size of circa 200 nm, transfersome suspensions were 
passed through polycarbonate membranes of 600 nm for 5 cycles, where 
vesicle size as well as PDI were reduced simultaneously after each cycle 
(Fig. 1a and b). After achieving vesicles sizes up to ~600 nm, these 
formulations were then passed through polycarbonate membranes of 
200 nm pore size. Similarly, reduction in vesicle size and PDI was also 
observed for 5 cycles (Fig. 1c and d). Whereas, more cycles through 200 
nm filters did not reduce the vesicle size, but showed increase in particle 
size as well as PDI, which may be associated with aggregation, fusion or 
acquiring electrostatic charges (Data not shown). It is important to know 
that using the Zetasizer instrument, a PDI value of 1 is considered the 
maximum particle size distribution within the sample; therefore a 
sample with PDI value close to 1 indicates that particles are highly 
polydispersed (i.e. have a broad size distribution) whilst a PDI of 0.1 
exhibit a narrow particle size distribution. 
Upon comparison of VMD values, all formulations did not achieve 
particle size of circa 200 nm, when passing through 600 nm and fol-
lowed by 200 nm polycarbonate membrane for 5 cycles. Moreover, it 
was found that formulations prepared with cholesterol were larger in 
size, when compared to formulations without cholesterol [31] (Fig. 2). 
Upon the addition of cholesterol, the hydrophobicity of particle surfaces 
may increase. This increase of surface hydrophobicity may cause par-
ticle aggregation and subsequently increase particle size. The thickness 
of phospholipid layer of membrane was also found to increase in the 
presence of cholesterol by 3 Å, when using low-angle X-ray diffraction 
spacing [32]. This increase in thickness due to cholesterol may decrease 
in the area per molecule of phospholipid in the plane of membrane, 
which ultimately increases the size of the vesicles. Moreover, it was also 
suggested that both cholesterol and surfactant compete to keep their 
place in the lipid bilayers and hence increase vesicle size in addition to 
an increase in bilayer packing density [33,34]. However, it was also 
identified that lipid vesicles are comparatively more prone to defor-
mation in the absence of cholesterol. The incorporation of cholesterol is 
known to stabilize vesicles by giving them rigidity and thus maintaining 
their structure [35,36]. Both SPC and DMPC possess relatively low phase 
transition temperatures (- 20 ◦C and 23 ◦C) and the incorporation of 
cholesterol stabilizes transfersome vesicles; whereas HSPC has a higher 
phase transition temperature (52 ◦C). At room temperature, HSPC be-
comes more rigid (due to its solidification), and hence stabilizes trans-
fersome vesicles. Additional incorporation of cholesterol molecules fills 
the gaps within the phospholipid and surfactant molecules (by inter-
acting with the core of membrane during annealing), and makes the 
transfersome membrane highly rigid; thus, reducing drug leakage from 
the vesicles [37–39]. This may be related to the change of the fluid phase 
phospholipid bilayer to a solid phase bilayer, due to the incorporation of 
cholesterol and hence the ability of transfersome bilayers to retain hy-
drophobic drugs is enhanced [40,41]. 
Upon comparison of the VMD values, formulations prepared using 
SPC as a phospholipid formed significantly smaller vesicles (p < 0.05) 
when compared to vesicles prepared from DMPC and HSPC. This may be 
related to the lower phase transition temperature of SPC i.e. - 20 ◦C, 
when compared to 23 ◦C and 52 ◦C of DMPC and HSPC, respectively 
(Fig. 2). The lower phase transition of the SPC formulation may keep the 
bilayer membrane more fluid, facilitating size reduction, whilst the 
higher phase transition temperatures of vesicles made from DMPC or 
HSPC can increase bilayer rigidity and promote resistance against 
sonication-driven fragmentation. Furthermore, surfactants are added 
into the formulation in order to enhance vesicles flexibility. Significantly 
smaller (p < 0.05) VMD of transfersome vesicles was achieved using 
Tween 80 as a surfactant than the incorporation of Span 80 or Span 20 
(Fig. 2). Tween 80 is water-soluble surfactant with a HLB value of 15, 
and therefore the presence of a water-soluble surfactant in transfersomes 
enabled lower vesicle size, when compared to the employment of Span 
80 or Span 20, which are oil soluble and water dispersible surfactants (i. 
e. HLB values of 4.3 and 8.6). It is suggested that the hydrophilic sur-
factant (Tween 80) covers the surface of the vesicles more, due to their 
hydrophilic moiety (higher HLB value) [42–44], when compared to 
Span 80 and Span 20. Moreover, Tween 80 may reduce the high inter-
facial tension of the vesicles (due to the hydrophilic head group) 
resulting in more consistent VMD and PDI, compared to other non-ionic 
surfactants used in transfersome formulations [45]. Additionally, Tween 
80 contains a longer hydrocarbon chain and, based on other literature 
reports, this may contribute in generating vesicles with a smaller size. 
Duangjit et al. have evaluated the effect of hydrocarbon chain length on 
the size of lipid vesicles and reported that; as the carbon chain length 
increases (from C4 to C16), particle size decreases [46]. However, 
contrasting results were also found in literature; where different sur-
factants demonstrated no significant change in the size of transfersome 
vesicles [47]. Further investigations by our research group and by other 
labs are needed to provide a better understanding about the relationship 
between surfactant structure/geometry and the resultant particle size. 
Additionally, water soluble surfactants cover the surface moiety of 
vesicles further, preventing transfersome aggregation. Moreover, the 
hydrophilicity of the surfactant head group also aids in lowering vesicle 
size, this may be associated with the smaller/short hydrophobic back-
bone. These results are in agreement with studies conducted by previous 
researchers [46,48]. Span 80, cholesterol and BDP are lipophilic 
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molecules and tend to lodge themselves within the lipid bilayers. Span 
80 as an oil-soluble surfactant may interact with the lipophilic chains of 
the phospholipids in further addition to the presence of lipophilic sub-
stances (i.e. cholesterol and BDP), which create a further competition 
with Span 80 on the phospholipid alkyl chains. The packing of these 
molecules in the bilayer membrane might be causative of the relatively 
large vesicle size [33,34]. This effect of increasing particle size was also 
observed in multilamellar vesicles [49] as well as in unilamellar vesicles 
[50]. Whereas, water dispersible surfactants (e.g. Span 20) may disperse 
along with the transfersome vesicles within the dispersion medium, 
enabling slightly larger VMD, when compared to transfersomes formu-
lated with Tween 80 surfactants (Fig. 2). The effect of surfactant on 
smaller to larger size of transfersomes vesicles were found in the 
following rank; Tween 80 < Span 20 < Span 80 (i.e. HLB values from 
higher to lower). However, by comparing PDI, no significant difference 
was observed between transfersome formulations (Fig. 2). Post soni-
cation, stability studies were conducted for all transfersome formula-
tions for 2 weeks at room and fridge temperatures (i.e. 25 ◦C and 6 ◦C, 
respectively). No significant differences (p > 0.05) were noted in terms 
of VMD, PDI and entrapment efficiency, and therefore were not included 
in the manuscript. 
In this study, three different phospholipids and three different sur-
factants were employed to prepare transfersome vesicles with or without 
cholesterol, in order to examine their impact on particle size and PDI. 
Criteria determined for the selection of optimum formulation for further 
studies (i.e. nebulization studies) was smaller particle size and lower PDI 
(to fit better in the small droplets with minimal fragmentation; this was 
found in previous investigation to help with increasing deposition of 
vesicles in the lower stage of the Impinger). An additional key parameter 
for a good formulation is its ability to entrap the highest possible pro-
portion of the drug. Thus, the best formulation should possess smallest 
vesicle size, in combination with lowest PDI and maximum drug 
entrapment. Thus, transfersomes formed using SPC as the phospholipid 
and Tween 80 as the surfactant without cholesterol demonstrated the 
best properties in terms of size. 
3.2. Zeta potential of transfersome vesicles 
Upon investigation of Zeta potential values, it was found that all the 
formulations had a negative charge (Fig. 3). The three phospholipids 
Fig. 3. Zeta potential of transfersome formulations (F1 – F18), prepared from three different phospholipids (SPC, DMPC and HSPC), three surfactants (Tween 80, 
Span 80 and Span 20) with and without the presence cholesterol. Data are mean ± SD, n = 3. 
Fig. 4. Entrapment efficiency of BDP in transfersome formulations (F1 – F18), prepared from three different phospholipids (SPC, DMPC and HSPC), three surfactants 
(Tween 80, Span 80 and Span 20) with and without cholesterol inclusion. Data are mean ± SD, n = 3. 
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used (i.e. SPC, DMPC and HSPC) are zwitterion compounds with an 
isoelectric point of 6–7, meaning that they are neutral compounds, and 
the surfactant used in the formulations are also non-ionic. It was also 
identified that some surfactants type and their concentrations greatly 
affect zeta potential values [7]. Moreover, formulations prepared with 
Span 80 demonstrated a higher negative charge (circa − 7.05 ± 1.15 to 
− 11.65 ± 1.21) than formulations prepared from Span 20 and Tween 80 
(Fig. 3). The presence of a charge could be beneficial in order to keep the 
formulation stable, as electrostatic repulsive forces tend to reduce 
vesicle aggregation and fusion. However, the negative charges are not 
substantially high and thus may possibly be attributed to trace amounts 
of impurities (though excipients used are of pharmaceutical grades, the 
purity of phospholipids SPC, DMPC and HSPC is 94%, 98% and 98% 
respectively; thus the percentage impurity of phospholipids may cause a 
mild surface charge). 
3.3. Entrapment efficiency of BDP in transfersome vesicles 
Upon comparison of phospholipid effect on entrapment efficiency, 
no significant difference (p > 0.05) was found. This suggests that 
entrapment efficiency of BDP was not affected by phospholipid type. 
However, it was recognized that entrapment efficiency was highly 
affected by the inclusion and exclusion of cholesterol, as well selection 
of surfactant type (Fig. 4). Cholesterol was incorporated in vesicles in 
order to make them rigid by filling the gaps between the assembled 
phospholipids within the bilayers of the liposomes (i.e. to form more 
ordered membrane) and hence reduce drug leakage [39]. However, it is 
important to know that both cholesterol and BDP are lipophilic mole-
cules and have a similar steroidal structure, hence compete for their 
accommodation in the concentric bilayers. Therefore, it is suggested that 
the incorporation of cholesterol decreases drug entrapment by housing 
in the bilayers of liposomes [16]. Similar findings were found where 
formulations without cholesterol exhibited significantly higher (p <
0.05) entrapment of BDP, when compared to transfersome vesicles with 
cholesterol included, irrespective of phospholipid type (i.e. SPC, DMPC 
and HSPC) (Fig. 4) [9]. Additionally, transfersomes are elastic/flexible 
vesicles (in the absence of cholesterol) and therefore during extrusion 
through polycarbonate membrane, they were successfully reduced in 
size, and hence high entrapment was achieved. Whereas, transfersomes 
containing cholesterol were more rigid, and hence their extrusion 
through membrane under pressure may have resulted in vesicle 
breakage and hence lower entrapment was attained due to drug leakage 
(Fig. 4). These results are in agreement with previous research con-
ducted by Duangjit et al. [31]. 
Surfactant selection is also important in order to achieve high drug 
entrapment. Span 80 in transfersome vesicles demonstrated lower drug 
entrapment when compared to Span 20 and Tween 80. As discussed in 
section 3.1, lipophilic surfactants (Span 80) also compete with lipophilic 
molecules (i.e. BDP and cholesterol) to assemble themselves in the bi-
layers, which may result in a larger vesicle size, but also leave less space 
for BDP entrapment, providing an explanation for the low entrapment 
observed (an average of 78% without cholesterol and 64% with 
cholesterol) (Fig. 4). Furthermore, it is also suggested that Span 80 
contains an unsaturated double bond in their alkyl carbon chain. The 
presence of double bond may bend the alkyl chain in the bilayers, and 
therefore lower bilayer domain available to house BDP (lipophilic drug 
molecule). Analogous results were also demonstrated by previous 
studies [51,52]. Span 20, a water dispersible surfactant demonstrated 
lower competition for accommodation into the vesicle structure, 
whereas, Tween 80 (water soluble surfactant) showed higher drug 
entrapment with in transfersome vesicles (an average of 96% without 
cholesterol and 84% with cholesterol) (Fig. 4). Similar results were also 
found where the employment of hydrophilic surfactants with high HLB 
values demonstrated high drug entrapment in vesicles [53]. 
In summary, transfersome vesicles prepared from SPC as a phos-
pholipid and Tween 80 as a surfactant without cholesterol demonstrated 
the highest BDP entrapment. A trend of higher BDP entrapment based on 
surfactant was identified as; Tween 80 > Span 20 > Span 80. 
3.4. Nebulization performance 
Based on aforementioned characterizations, formulations with 
Tween 80 as a surfactant without cholesterol were carried through for 
testing with nebulizers. Specially, formulations F1, F7 and F13 were 
selected for further analysis. Air-jet, Ultrasonic and Vibrating mesh 
nebulizers were employed for the nebulization performance using 5 ml 
of transfersome formulation. 
3.4.1. Nebulization and sputtering time of transfersome formulations 
Nebulization to dryness was determined for transfersome 
Fig. 5. Nebulization time (vertical bars) and sputtering time (horizontal lines) of BDP-loaded transfersome selected formulations (F1, F7 and F13) were determined 
using three nebulizers (i.e. Air-jet, Ultrasonic and Vibrating mesh). All these three formulations containing Tween 80 as a surfactant; whereas, in terms of phos-
pholipid, F1, F7 and F13 consist of SPC, DMPC and HSPC respectively. Data are mean ± SD, n = 3. 
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suspensions for all three formulations, using three nebulizers. Nebuli-
zation time is the time required for aerosolization, where the formation 
of the aerosol becomes erratic. Using Air-jet, Ultrasonic and Vibrating 
mesh nebulizers for the nebulization time of F1, F7 and F13 formula-
tions, a significant difference was observed in terms of nebulization time 
(p < 0.05), with an order in terms of time as follows; Vibrating Mesh >
Air-jet > Ultrasonic nebulizer (Fig. 5). Nebulization performance (e.g. 
droplet size, nebulization time, etc.) is highly dependent on formulation 
properties, such as; viscosity, surface tension [54,55] and type of ions in 
the solution [56]. These effects are interactive with the nebulizer design 
and its operating mechanism [55]. For vesicle-based formulations, the 
influence on nebulization performance is complicated and multifacto-
rial, considering that these formulations are neither Newtonian solu-
tions nor traditional non-Newtonian dispersions, but rather are a special 
type of dispersion made from liquid crystalline constituents, interplay-
ing with a dispersion medium that is made from mainly water and 
partially other ingredients (e.g. free surfactant molecules that are not 
associated with the vesicles). For nebulization of the vesicle-based for-
mulations, the main factors influencing nebulization performance are 
vesicle size, vesicle membrane rigidity (i.e. judged through lipid phase 
transition temperature), and nebulizer operation mechanism and design 
[55]. Vesicles of a large size may demonstrate prolonged nebulization 
time and higher residual volumes, as the vesicles have to be first frag-
mented by shearing within the nebulizer, in order to fit into the size of 
the forming aerosol droplets. Additionally, higher membrane rigidity 
makes it more difficult for nebulizers to break up the vesicles into 
smaller ones, prolonging nebulization time and reducing output. Large 
vesicles tend to stay in the reservoir of jet and mesh nebulizers, and 
block the mesh apertures of mesh nebulizer, resulting in prolongation of 
nebulization time [2]. Nebulization time is also dependent on nebulizer 
type and design, with performance of Ultrasonic and Vibrating mesh 
devices being more formulation-sensitive compared to Air-jet nebu-
lizers. Transfersomes are vesicles with limited reports in literature for 
nebulization delivery; thus, it is worth investigating whether their par-
ticle size would influence the performance of the resultant aerosol, and 
whether their proposed “ultra-deformability” can ameliorate the nega-
tive influence of vesicle size on nebulization performance (time and 
output). High viscosity of the formulation may slow the aerosolization 
rate from lipid-based formulations in the nebulizer reservoir and hence 
can prolong nebulization time [25,55,57,58]. Moreover, the effect of 
surface tension on nebulization is not well understood. On one hand, it 
has been shown that low surface tension might be advantageous in 
shortening the nebulization time [55,59]. On the other hand, the pres-
ence of surfactant may cause formation of foam through 
aerosolization-induced shearing/vigorous mixing, which may increase 
the nebulization sputtering time [24]. In this study, we have focused on 
investigating the influence of vesicle size and bilayer composition on 
aerosol performance. 
Employing individual nebulizers i.e. Air-jet, Ultrasonic and Vibrating 
mesh, no significant difference (p > 0.05) was found between F1, F7 and 
F13 formulations. However, for Vibrating mesh nebulizer, nebulization 
time was significantly higher (p < 0.05) when compared to Air-jet and 
Ultrasonic nebulizers (Fig. 5). This may be associated with the principle 
of Vibrating mesh nebulizer, where the low energy of atomization may 
lengthen the nebulization time [55]. Additionally, it may further cause 
the aggregation/fusion of nanoparticles, which may cause the blockage 
of mesh and hence be responsible for longer nebulization time [29]. 
Upon analysis, the Ultrasonic nebulizer, comparatively exhibited 
significantly shorter (p < 0.05) nebulization time (under 20 min) 
(Fig. 5). This is suggested to be due to the function of Ultrasonic nebu-
lizer, where the movement generated by the piezoelectric crystal en-
ables aerosol formation without impacting upon the transfersome 
vesicle size, and hence shorter nebulization time was achieved. Similar 
results were also reported for a shorter nebulization using an Ultrasonic 
nebulizer [29,60]. 
The nebulization time of the Air-jet nebulizer was found to be circa 
26 min, significantly higher (p < 0.05) than the Ultrasonic nebulizer and 
significantly lower (p < 0.05) than the Vibrating mesh nebulizer (Fig. 5). 
The Air-jet nebulizer may increase formulation viscosity, which is 
associated with a decrease in temperature [13,24]. Higher viscosity of 
Fig. 6. (a) Mass output and, (b) output rate of BDP-loaded transfersome formulations (F1, F7 and F13) were found using three nebulizers (i.e. Air-jet, Ultrasonic and 
Vibrating mesh). All these three formulations containing Tween 80 as a surfactant; whereas, in terms of phospholipid, F1, F7 and F13 consist of SPC, DMPC and HSPC 
respectively. Data are mean ± SD, n = 3. 
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formulation may lengthen nebulization time, due to the greater adher-
ence of the formulation (aerosol droplets) to the internal walls of Air-jet 
nebulizer, followed by delayed/slower deflection of formulation to the 
nebulizer reservoir. Comparable finding in terms of nebulization time 
were also demonstrated by previous studies [59,61]. 
Sputtering time also differed significantly (p < 0.05) across the 
different nebulizers used, whereas, no effect was observed by altering 
the formulation type (Fig. 5). Higher to lower sputtering time by neb-
ulizer’s type were ranked in the following order; Air-jet > Ultrasonic >
Vibrating mesh. The longer sputtering time by Air-jet nebulizer is related 
to the higher viscosity caused by the nebulizer during aerosolization, 
where formulations deposited on the internal walls (after initial aerso-
lization) took longer time for formulation deflection back into the 
nebulizer reservoir for the re-aerosolization process. The Vibrating mesh 
nebulizer retained a smaller portion of formulation following nebuli-
zation (the majority of the formulation was aerosolized and therefore 
took longer nebulization time) and hence demonstrated a shorter sput-
tering time compared to Air-jet and Ultrasonic nebulizers (Fig. 5). The 
Ultrasonic nebulizer generates aerosol by a mechanism called capillary 
wave formation followed by fragmentation. However, Ultrasonic neb-
ulizers are not able to convert lower formulations (remaining in the 
nebulizer reservoir) into aerosol by capillary wave formation and 
therefore transfersome suspensions remained in the nebulizer (also 
terms as “dead or residual volume”). As a result a longer sputtering time 
was observed. 
3.4.2. Mass output and aerosol output rate of transfersome formulations 
Irrespective of nebulizer type, nebulization was carried out to dry-
ness or complete nebulization time (combined time duration of nebuli-
zation time and sputtering time), it is not possible to achieve 100% mass 
output. Significantly lower (p < 0.05) mass output was demonstrated by 
the Ultrasonic nebulizer (an average of 70%) when compared to Air-jet 
and Vibrating mesh nebulizers (Fig. 6a). This may be related to the 
higher amount of residual volume remaining in the nebulizer reservoir, 
post nebulization. Whereas, higher mass output by the Vibrating mesh 
nebulizer (circa 92%) is linked with a lower residual volume (Fig. 6a). 
The lower residual volume of the formulation by the Vibrating mesh 
nebulizer is directly linked to the design of mesh nebulizer, where a 
slanting position of reservoir (holding formulation) maximises its 
dissemination through the mesh in order to generate aerosol. Analogous 
results were also found by previous studies, where a lower residual 
volume was found for Vibrating mesh nebulizers when compared to 
Ultrasonic and Air-jet nebulizers [29,62,63]. Furthermore, similar re-
sults were found when liposomes as lipid-based formulations were 
employed for nebulization (a trend of higher to lower mass output; 
Vibrating mesh > Jet > Ultrasonic nebulizer) [27]. It was also identified 
that formulation type did not affect aerosolization and hence mass 
output was not compromised/affected. These results indicated that 
method of action and design of nebulizers influenced mass output rather 
than formulation type. 
Upon investigation, the three nebulizers used showed significantly 
different (p < 0.05) output rates. Based on the results obtained in this 
study, it was identified that nebulizer performance in terms of output 
rate is directly related to the nebulization time and mass output. Shorter 
nebulization times or higher mass output, results in higher output rate 
Fig. 7. Deposition of BDP in the nebulizer reservoir, upper stage and lower stage of TSI using transfersome formulations (F1, F7 and F13), employing three nebulizers 
(Air-jet, Ultrasonic and Vibrating mesh). All these three formulations containing Tween 80 as a surfactant; whereas, in terms of phospholipid, F1, F7 and F13 consist 
of SPC, DMPC and HSPC respectively. Data are mean ± SD, n = 3. 
Table 2 
Nebulization performance of Air-jet, Ultrasonic and Vibrating mesh nebulizers 
using formulations F1, F7 and F13 employing emitted dose (ED), fine particle 
dose (FPD) and fine particle fraction (FPF) using TSI. Data are mean ± SD, n = 3.  
Formulations ED (%) FPD (%) FPF (%) 
Air-jet nebulizer 
F1 81.85 ± 6.10 68.24 ± 5.38 83.37 ± 7.41 
F7 74.78 ± 5.88 23.87 ± 3.33 31.92 ± 5.06 
F13 38.33 ± 7.24 22.94 ± 3.64 59.83 ± 5.62 
Ultrasonic nebulizer 
F1 74.08 ± 6.77 55.84 ± 4.95 75.38 ± 6.35 
F7 77.01 ± 5.14 25.19 ± 3.91 32.71 ± 5.54 
F13 42.86 ± 6.42 27.75 ± 3.58 64.75 ± 4.67 
Vibrating mesh nebulizer 
F1 74.91 ± 7.33 57.53 ± 5.66 76.80 ± 7.17 
F7 66.60 ± 6.54 21.24 ± 3.48 31.89 ± 4.38 
F13 35.48 ± 5.47 21.54 ± 3.71 60.71 ± 5.54  
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per min (Figs. 5a and 6a). The Ultrasonic nebulizer demonstrated an 
average output rate of circa 200 mg/min, which is a significantly higher 
(p < 0.05) output rate than both counterpart nebulizers (Fig. 6b). The 
Ultrasonic nebulizer demonstrated a shorter nebulization time as well as 
higher mass output. A significantly lower (p < 0.05) output rate was 
exhibited by the Vibrating mesh nebulizer regardless of formulation type 
(approximately 76 mg/min), which is 62% lower than the output rate of 
the Ultrasonic nebulizer (Fig. 6b). As explained, low energy atomization 
as well as blockage of aperture mesh plate (due to aggregation/fusion) 
may extend the nebulization time and hence reduce output rate per min 
[29]. The Air-jet nebulizer showed an output rate higher than the 
Vibrating mesh and lower than Ultrasonic nebulizer i.e. an average of 
152 mg/min (Fig. 6b). This output rate is 24% smaller than the Ultra-
sonic nebulizer, and 50% higher than the Vibrating mesh nebulizer. 
Overall, it was found that Ultrasonic nebulizer is superior with 
regards to higher mass output and output rate, regardless of formulation 
type (i.e. F1, F7 or F13), when compared to the Air-jet and Vibrating 
mesh nebulizers. 
3.5. BDP deposition in two-stage Impinger (TSI), post nebulization 
Post nebulization, deposition of BDP in both the upper and lower 
stages (also referred as emitted dose (ED)) of TSI and formulations 
remaining in the nebulizer reservoir containing BDP was determined. 
Based on formulation type i.e. F1, F7 and F13, the delivered BDP in the 
two stages (combined in upper stage and lower stage) regardless of 
nebulizer type was 77%, 73% and 39%, respectively (Fig. 7 and Table 2). 
Indicating that both F1 and F7 formulations are more suitable than the 
F13 formulation. This difference in drug delivery to the two stages of TSI 
may be associated with the lower phase transition temperatures of SPC 
and DMPC (- 20 and 23 ◦C) for formulations F1 and F7, when compared 
to the higher phase transition temperature of HSPC (i.e. 52 ◦C) [2]. 
Moreover, when using the Air-jet nebulizer, formulation F1 demon-
strated a higher ED, when compared to the counterpart formulations as 
well as nebulizers (Table 2). Formulations with a lower phase transition 
temperature are easier to prepare (in an ambient/room temperature) 
and are more stable than formulations with a higher phase transition 
temperature (keeping that temperature throughout their preparation) 
and hence are associated with less stability (temperature change from 
elevated to room), which may affect the integrity of the vesicles. 
Upon comparison of FPD, formulation F1 (prepared from SPC) 
showed a significantly higher (p < 0.05) BDP deposition in the lower 
stage of TSI (61%), representing deep lung deposition and considered as 
a desirable formulation (irrespective of nebulizer type). F7 and F13 
formulations deposited less than half of BDP nebulized in the lower stage 
(Fig. 7 and Table 2). Formulation F7, demonstrated significantly higher 
(p < 0.05) BDP deposition in the upper stage of TSI (49%), and it was 
thus considered an appropriate formulation for achieving pharmaco-
logical action required in the upper respiratory tract (Fig. 7). This may 
be related to the lower phase transition temperature of the phospholipid 
SPC, which possibly increases bilayer fluidity and vesicle flexibility, 
regardless of the type of nebulizer. Whereas, the other phospholipids 
may make the bilayers more rigid and less flexible (related to their phase 
transition temperatures), and increase the retention of vesicles in the 
nebulizer reservoir (Fig. 7, for F13) or cause increased deposition in the 
upper stage of the Impinger (Fig. 7, formulation F7) for vesicles prepared 
from HSPC and DMPC. Contrastingly on average, 61% of BDP remained 
in the nebulizer reservoir for the F13 formulation, post nebulization. 
Formulation F1 showed significantly higher (p < 0.05) FPF for all three 
nebulizers, when compared to the F7 and F13 formulations. Addition-
ally, a trend of higher FPF value based on nebulizer performance using 
F1 formulation was identified as; Air-jet > Vibrating mesh > Ultrasonic 
nebulizer (83%, 77% and 75%) (Table 2). 
Overall, it was found that the F1 formulation is ideal for targeting 
deep lung deposition, and the F7 formulation for deposition in the upper 
area of the pulmonary system, regardless of nebulizer type. 
3.6. Morphology of transfersome vesicles via TEM 
TEM was used to determine the morphology of selected transfersome 
formulations i.e. F1, F7 and F13. Images captured suggested that 
transfersome vesicles were spherical to slightly oval in shape (Fig. 8). 
These images confirmed the successful formation of transfersome 
vesicles. 
4. Conclusions 
Novel BDP-loaded transfersomes were successfully prepared using 
various phospholipids (SPC, DMPC and HSPC), surfactants (Tween 80, 
Span 80 and Span 20) with and without cholesterol, using an extrusion 
method. The incorporation of Tween 80 demonstrated significantly 
smaller VMD, PDI, Zeta potential and higher entrapment efficiency. This 
indicated that physicochemical properties of vesicular system were not 
affected by the phospholipid type, but surfactant selection without 
cholesterol inclusion. Based on the aforementioned characterization, 
only three (i.e. F1, F7 and F13) out of the eighteen formulations 
developed were selected for nebulization performance. Aerosols were 
generated from transfersome suspensions, employing; Air-jet, Ultrasonic 
and Vibrating mesh nebulizers. The Ultrasonic nebulizer showed shorter 
nebulization time, followed by Air-jet, whereas a significantly longer 
time was noted for the Vibrating mesh nebulizer. The mass output from 
the nebulizers were less than the total mass used, suggesting 
Fig. 8. TEM images of transfersome formulations, (a) F1, (b) F7, and (c) F13. These images are typical of three different experiments.  
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accumulation/retention of transfersome formulation in the nebulizer’s 
reservoir, related to the design and mechanism of nebulizers aerosol 
generation. Additionally, output rate of formulations using Air-jet, Ul-
trasonic and Vibrating mesh nebulizers differed significantly, and were 
found in the order of Ultrasonic > Air-jet > Vibrating mesh. Based on 
BDP deposition in stages of TSI, the Ultrasonic nebulizer demonstrated 
circa 49% and 23% DDP deposition in the upper and lower stages 
respectively when using formulation F7; Whereas, the Air-jet nebulizer 
demonstrated approximately 16% and 61% of BDP deposition using F1 
formulation in the upper and lower stages, respectively. Moreover, the 
Air-jet nebulizer exhibited higher ED and FPF, when using the F1 
formulation, as compared to counterpart nebulizers and formulations. 
These results indicated (based on physicochemical properties, nebulizer 
performance and BDP deposition) that the F1 formulation paired with 
the Air-jet nebulizer is a suitable combination for peripheral drug 
deposition, whereas a combination of the F7 formulation with the Ul-
trasonic nebulizer is ideal for targeting the upper respiratory tract. 
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